| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterococcus faecalis | 26 | 2025 | 71 | 3.720 |
Why?
|
| Bystander Effect | 7 | 2025 | 16 | 2.440 |
Why?
|
| Colorectal Neoplasms | 11 | 2025 | 142 | 2.300 |
Why?
|
| Gram-Positive Bacterial Infections | 16 | 2019 | 91 | 2.040 |
Why?
|
| Macrophages | 8 | 2025 | 306 | 1.510 |
Why?
|
| Colon | 6 | 2014 | 123 | 1.490 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2025 | 138 | 1.110 |
Why?
|
| DNA Damage | 6 | 2016 | 152 | 1.100 |
Why?
|
| Superoxides | 7 | 2008 | 62 | 1.070 |
Why?
|
| Enterococcus | 5 | 2019 | 19 | 0.960 |
Why?
|
| Aldehydes | 5 | 2025 | 55 | 0.930 |
Why?
|
| Intestines | 6 | 2016 | 118 | 0.780 |
Why?
|
| Intestinal Mucosa | 9 | 2019 | 198 | 0.780 |
Why?
|
| Epithelial Cells | 5 | 2016 | 266 | 0.740 |
Why?
|
| Colonic Neoplasms | 4 | 2014 | 122 | 0.710 |
Why?
|
| Carcinogenesis | 2 | 2021 | 81 | 0.710 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2016 | 120 | 0.680 |
Why?
|
| Cyclooxygenase 2 | 3 | 2016 | 68 | 0.670 |
Why?
|
| Animals | 32 | 2025 | 10709 | 0.640 |
Why?
|
| Food Contamination | 1 | 2019 | 22 | 0.620 |
Why?
|
| Probiotics | 1 | 2019 | 19 | 0.620 |
Why?
|
| Inflammation | 3 | 2021 | 668 | 0.590 |
Why?
|
| Neoplastic Stem Cells | 3 | 2020 | 141 | 0.540 |
Why?
|
| Cytotoxins | 5 | 2019 | 51 | 0.490 |
Why?
|
| Humans | 58 | 2025 | 28912 | 0.490 |
Why?
|
| Mice | 18 | 2025 | 4812 | 0.460 |
Why?
|
| Nerve Growth Factors | 2 | 2012 | 24 | 0.450 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 51 | 0.440 |
Why?
|
| Mice, Knockout | 9 | 2025 | 876 | 0.440 |
Why?
|
| Glutathione Transferase | 3 | 2025 | 33 | 0.440 |
Why?
|
| Adenoma | 2 | 2010 | 61 | 0.440 |
Why?
|
| Aneuploidy | 2 | 2015 | 21 | 0.400 |
Why?
|
| Drug Resistance, Microbial | 8 | 2019 | 36 | 0.390 |
Why?
|
| Chromosomal Instability | 2 | 2016 | 21 | 0.380 |
Why?
|
| Autocrine Communication | 1 | 2011 | 7 | 0.360 |
Why?
|
| Nitrogen Oxides | 2 | 2010 | 41 | 0.360 |
Why?
|
| Bacterial Infections | 2 | 2004 | 56 | 0.360 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2022 | 285 | 0.360 |
Why?
|
| HCT116 Cells | 4 | 2014 | 54 | 0.350 |
Why?
|
| Colitis | 3 | 2025 | 54 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 251 | 0.350 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2000 | 10 | 0.340 |
Why?
|
| Bioterrorism | 4 | 2003 | 28 | 0.330 |
Why?
|
| Endocarditis, Bacterial | 4 | 1996 | 15 | 0.330 |
Why?
|
| Genes, APC | 1 | 2010 | 14 | 0.320 |
Why?
|
| Bacteremia | 6 | 1999 | 81 | 0.310 |
Why?
|
| Risk Factors | 8 | 2019 | 2129 | 0.300 |
Why?
|
| Hemin | 1 | 2008 | 14 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 7 | 2019 | 536 | 0.290 |
Why?
|
| Disease Outbreaks | 3 | 2019 | 54 | 0.270 |
Why?
|
| Extracellular Space | 4 | 2006 | 26 | 0.270 |
Why?
|
| Free Radicals | 2 | 2004 | 39 | 0.270 |
Why?
|
| Genes, Bacterial | 3 | 1999 | 109 | 0.260 |
Why?
|
| Immunity, Innate | 2 | 2019 | 232 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 34 | 0.250 |
Why?
|
| Anti-Infective Agents | 3 | 2012 | 78 | 0.240 |
Why?
|
| Sex Attractants | 2 | 1995 | 5 | 0.230 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 686 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 634 | 0.230 |
Why?
|
| Disease Models, Animal | 7 | 2016 | 1510 | 0.220 |
Why?
|
| Phytic Acid | 1 | 2004 | 4 | 0.220 |
Why?
|
| Enterococcus faecium | 3 | 2019 | 8 | 0.220 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 465 | 0.220 |
Why?
|
| Hydrogen Peroxide | 2 | 2002 | 145 | 0.220 |
Why?
|
| Smallpox | 3 | 2003 | 6 | 0.220 |
Why?
|
| Rectal Neoplasms | 1 | 2004 | 10 | 0.220 |
Why?
|
| Bacterial Proteins | 4 | 1999 | 498 | 0.210 |
Why?
|
| Cross Infection | 2 | 2003 | 37 | 0.210 |
Why?
|
| Air Microbiology | 1 | 2003 | 3 | 0.210 |
Why?
|
| beta Catenin | 2 | 2022 | 66 | 0.210 |
Why?
|
| Aspergillosis | 1 | 2003 | 11 | 0.200 |
Why?
|
| Aspergillus | 1 | 2003 | 9 | 0.200 |
Why?
|
| Iron | 1 | 2004 | 117 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 329 | 0.200 |
Why?
|
| Hospitals, Teaching | 2 | 2000 | 26 | 0.190 |
Why?
|
| Interleukin-10 | 3 | 2025 | 74 | 0.190 |
Why?
|
| United States | 8 | 2019 | 2227 | 0.190 |
Why?
|
| Electron Spin Resonance Spectroscopy | 4 | 2004 | 35 | 0.190 |
Why?
|
| Hydroxyl Radical | 1 | 2002 | 7 | 0.190 |
Why?
|
| Genetic Loci | 2 | 2019 | 77 | 0.190 |
Why?
|
| Male | 22 | 2013 | 13947 | 0.190 |
Why?
|
| Bacteria | 2 | 2004 | 286 | 0.180 |
Why?
|
| Coculture Techniques | 2 | 2012 | 55 | 0.180 |
Why?
|
| Vitamin K 2 | 1 | 2001 | 8 | 0.180 |
Why?
|
| Hepatocytes | 2 | 2020 | 88 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 4 | 2008 | 278 | 0.180 |
Why?
|
| Oxidoreductases | 1 | 2001 | 57 | 0.180 |
Why?
|
| Cell Line | 2 | 2014 | 701 | 0.180 |
Why?
|
| Dysbiosis | 1 | 2021 | 15 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 1660 | 0.170 |
Why?
|
| Netrin-1 | 2 | 2012 | 6 | 0.170 |
Why?
|
| Hypocalcemia | 1 | 2000 | 1 | 0.170 |
Why?
|
| Female | 21 | 2014 | 15651 | 0.170 |
Why?
|
| Magnesium Sulfate | 1 | 2000 | 4 | 0.170 |
Why?
|
| Middle Aged | 16 | 2013 | 7420 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2000 | 22 | 0.160 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2010 | 9 | 0.160 |
Why?
|
| Magnesium | 1 | 2000 | 42 | 0.160 |
Why?
|
| Streptococcal Infections | 2 | 1991 | 37 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2000 | 36 | 0.160 |
Why?
|
| Histones | 2 | 2011 | 96 | 0.160 |
Why?
|
| Food Safety | 1 | 2019 | 8 | 0.160 |
Why?
|
| Perforin | 1 | 2019 | 12 | 0.160 |
Why?
|
| NF-kappa B | 2 | 2012 | 191 | 0.160 |
Why?
|
| Food Microbiology | 1 | 2019 | 25 | 0.150 |
Why?
|
| Virulence Factors | 1 | 2019 | 45 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 46 | 0.150 |
Why?
|
| Rats | 4 | 2004 | 1590 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 1351 | 0.150 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 147 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 1 | 1998 | 14 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 1998 | 23 | 0.140 |
Why?
|
| Medical Records | 1 | 1998 | 51 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 92 | 0.140 |
Why?
|
| Bacterial Vaccines | 1 | 1998 | 29 | 0.140 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 20 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 173 | 0.140 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 167 | 0.140 |
Why?
|
| Virulence | 6 | 2003 | 153 | 0.140 |
Why?
|
| Lyme Disease | 3 | 1992 | 26 | 0.140 |
Why?
|
| Intestinal Neoplasms | 2 | 2010 | 15 | 0.130 |
Why?
|
| Cricetinae | 3 | 2006 | 131 | 0.130 |
Why?
|
| Molecular Sequence Data | 7 | 2001 | 1056 | 0.130 |
Why?
|
| Enterobacteriaceae | 1 | 2016 | 8 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 16 | 0.130 |
Why?
|
| SEER Program | 3 | 2013 | 47 | 0.130 |
Why?
|
| Conjugation, Genetic | 2 | 1995 | 11 | 0.130 |
Why?
|
| Adult | 14 | 2013 | 8038 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2016 | 288 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2016 | 52 | 0.120 |
Why?
|
| Streptomycin | 3 | 1992 | 14 | 0.120 |
Why?
|
| Blotting, Western | 3 | 2013 | 515 | 0.120 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2016 | 12 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 26 | 0.120 |
Why?
|
| Plasmids | 2 | 1995 | 126 | 0.120 |
Why?
|
| Mucins | 1 | 2016 | 25 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 114 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 120 | 0.120 |
Why?
|
| Crohn Disease | 2 | 2004 | 32 | 0.120 |
Why?
|
| Polysaccharides | 1 | 2016 | 65 | 0.120 |
Why?
|
| Legislation, Medical | 2 | 1994 | 2 | 0.110 |
Why?
|
| Symbiosis | 1 | 2015 | 37 | 0.110 |
Why?
|
| Histoplasmosis | 1 | 1994 | 10 | 0.110 |
Why?
|
| Cell Survival | 3 | 2016 | 419 | 0.110 |
Why?
|
| Malpractice | 1 | 1994 | 8 | 0.110 |
Why?
|
| Aged | 10 | 2013 | 5604 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 50 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 90 | 0.110 |
Why?
|
| Specialization | 1 | 1994 | 19 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 75 | 0.110 |
Why?
|
| Patients | 1 | 1994 | 17 | 0.110 |
Why?
|
| Phenylalanine | 2 | 2004 | 24 | 0.100 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.100 |
Why?
|
| Virus Replication | 1 | 2013 | 66 | 0.100 |
Why?
|
| Mutation | 3 | 2019 | 868 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 49 | 0.100 |
Why?
|
| Time Factors | 3 | 2011 | 1615 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2004 | 131 | 0.100 |
Why?
|
| Microtubules | 1 | 2013 | 90 | 0.100 |
Why?
|
| Microbiota | 1 | 2015 | 98 | 0.100 |
Why?
|
| Gentamicins | 2 | 1991 | 15 | 0.100 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 25 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 780 | 0.100 |
Why?
|
| Leukemoid Reaction | 1 | 1992 | 1 | 0.100 |
Why?
|
| Pheromones | 1 | 1992 | 7 | 0.100 |
Why?
|
| Nasal Decongestants | 1 | 1992 | 2 | 0.100 |
Why?
|
| Phenylephrine | 1 | 1992 | 13 | 0.100 |
Why?
|
| Digestive System | 1 | 1992 | 16 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 111 | 0.100 |
Why?
|
| Base Sequence | 5 | 2016 | 589 | 0.100 |
Why?
|
| Amino Acid Sequence | 6 | 2001 | 697 | 0.100 |
Why?
|
| Antitubercular Agents | 2 | 1998 | 16 | 0.090 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1992 | 19 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2012 | 65 | 0.090 |
Why?
|
| Protein C | 1 | 2012 | 38 | 0.090 |
Why?
|
| Stathmin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Tetraploidy | 1 | 2011 | 2 | 0.090 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2011 | 6 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 198 | 0.090 |
Why?
|
| Ehrlichiosis | 2 | 2001 | 5 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2006 | 1022 | 0.090 |
Why?
|
| Spindle Apparatus | 1 | 2011 | 52 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 1992 | 103 | 0.090 |
Why?
|
| Streptococcus | 1 | 1991 | 17 | 0.090 |
Why?
|
| RNA Interference | 1 | 2011 | 137 | 0.090 |
Why?
|
| Mycoses | 1 | 2011 | 9 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 13 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2011 | 32 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 149 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1991 | 12 | 0.090 |
Why?
|
| Sepsis | 1 | 2012 | 86 | 0.090 |
Why?
|
| Biopsy | 1 | 2011 | 208 | 0.090 |
Why?
|
| Transfection | 1 | 2011 | 319 | 0.080 |
Why?
|
| DNA, Bacterial | 4 | 2001 | 310 | 0.080 |
Why?
|
| Colony Count, Microbial | 3 | 2005 | 82 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2011 | 69 | 0.080 |
Why?
|
| Lymphoma | 1 | 2010 | 26 | 0.080 |
Why?
|
| Sarcoma | 1 | 2010 | 29 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2010 | 66 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 29 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 11 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2012 | 266 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 58 | 0.080 |
Why?
|
| Carcinoma | 1 | 2010 | 74 | 0.080 |
Why?
|
| DNA Transposable Elements | 2 | 2001 | 34 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 140 | 0.080 |
Why?
|
| Incidence | 4 | 2012 | 572 | 0.070 |
Why?
|
| Smad3 Protein | 1 | 2009 | 10 | 0.070 |
Why?
|
| G2 Phase | 1 | 2008 | 15 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 17 | 0.070 |
Why?
|
| Anaphase | 1 | 2008 | 30 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2000 | 174 | 0.070 |
Why?
|
| Escherichia coli | 3 | 2006 | 339 | 0.070 |
Why?
|
| Vancomycin | 3 | 1996 | 59 | 0.070 |
Why?
|
| Infection Control | 2 | 2000 | 33 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 513 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 79 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2008 | 163 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 472 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2010 | 898 | 0.070 |
Why?
|
| Enzyme Induction | 1 | 2006 | 28 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 19 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 37 | 0.060 |
Why?
|
| Gamma Rays | 1 | 2006 | 27 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2006 | 48 | 0.060 |
Why?
|
| Smallpox Vaccine | 2 | 2003 | 3 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2006 | 80 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2020 | 133 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 300 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 302 | 0.060 |
Why?
|
| HIV Infections | 2 | 2001 | 165 | 0.060 |
Why?
|
| Enterocolitis | 1 | 2005 | 5 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 490 | 0.060 |
Why?
|
| Phenotype | 3 | 2005 | 686 | 0.060 |
Why?
|
| Ehrlichia | 2 | 2001 | 2 | 0.060 |
Why?
|
| DNA Primers | 2 | 1995 | 147 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2005 | 45 | 0.060 |
Why?
|
| Antioxidants | 1 | 2006 | 224 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2025 | 88 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 483 | 0.060 |
Why?
|
| Carcinogens | 1 | 2004 | 39 | 0.050 |
Why?
|
| HIV-1 | 2 | 2001 | 59 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2012 | 2638 | 0.050 |
Why?
|
| Glutathione Peroxidase | 1 | 2004 | 26 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 452 | 0.050 |
Why?
|
| Air Conditioning | 1 | 2003 | 1 | 0.050 |
Why?
|
| Adolescent | 6 | 2013 | 3199 | 0.050 |
Why?
|
| DNA, Fungal | 1 | 2003 | 9 | 0.050 |
Why?
|
| Biotechnology | 1 | 2003 | 17 | 0.050 |
Why?
|
| Ventilation | 1 | 2003 | 7 | 0.050 |
Why?
|
| Feces | 2 | 1996 | 117 | 0.050 |
Why?
|
| Young Adult | 4 | 2013 | 2841 | 0.050 |
Why?
|
| Air Pollution, Indoor | 1 | 2003 | 14 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2001 | 378 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 381 | 0.050 |
Why?
|
| Genotype | 2 | 1995 | 461 | 0.050 |
Why?
|
| Nitrobenzenes | 1 | 2002 | 4 | 0.050 |
Why?
|
| Diet | 1 | 2004 | 241 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 23 | 0.050 |
Why?
|
| Calgranulin B | 1 | 2022 | 18 | 0.050 |
Why?
|
| Quinolones | 1 | 2022 | 22 | 0.050 |
Why?
|
| Tyrosine | 1 | 2002 | 92 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2002 | 17 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2002 | 71 | 0.050 |
Why?
|
| Xanthine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Xanthine Oxidase | 1 | 2002 | 5 | 0.050 |
Why?
|
| Comet Assay | 1 | 2002 | 5 | 0.050 |
Why?
|
| Chemokines | 1 | 2022 | 74 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 82 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2002 | 39 | 0.050 |
Why?
|
| Antigens, Bacterial | 2 | 2005 | 165 | 0.050 |
Why?
|
| Ileum | 1 | 2002 | 26 | 0.050 |
Why?
|
| CHO Cells | 1 | 2002 | 96 | 0.050 |
Why?
|
| Catalase | 1 | 2002 | 49 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2004 | 273 | 0.050 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2001 | 4 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 38 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 3 | 1999 | 149 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2001 | 153 | 0.040 |
Why?
|
| Survival Rate | 3 | 2010 | 432 | 0.040 |
Why?
|
| Vaccination | 1 | 2002 | 194 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 270 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2019 | 246 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 292 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2001 | 101 | 0.040 |
Why?
|
| Foscarnet | 1 | 2000 | 1 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2000 | 24 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 42 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 102 | 0.040 |
Why?
|
| Oklahoma | 4 | 1998 | 1055 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 66 | 0.040 |
Why?
|
| Formularies as Topic | 1 | 2000 | 1 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2000 | 138 | 0.040 |
Why?
|
| Species Specificity | 2 | 2001 | 195 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 78 | 0.040 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Carbapenems | 1 | 2019 | 6 | 0.040 |
Why?
|
| Calcium | 1 | 2000 | 243 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2000 | 422 | 0.040 |
Why?
|
| Teichoic Acids | 1 | 2019 | 18 | 0.040 |
Why?
|
| Operon | 1 | 2019 | 40 | 0.040 |
Why?
|
| Ethambutol | 1 | 1998 | 1 | 0.040 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1998 | 3 | 0.040 |
Why?
|
| Length of Stay | 1 | 2000 | 245 | 0.040 |
Why?
|
| Hospitals | 1 | 2019 | 77 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 73 | 0.040 |
Why?
|
| Prognosis | 2 | 2011 | 811 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2000 | 464 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2019 | 96 | 0.040 |
Why?
|
| Regression Analysis | 1 | 1998 | 211 | 0.040 |
Why?
|
| Colonoscopy | 1 | 1998 | 60 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 157 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2002 | 677 | 0.030 |
Why?
|
| Agar | 1 | 1997 | 4 | 0.030 |
Why?
|
| Bacteroides Infections | 1 | 1997 | 2 | 0.030 |
Why?
|
| Bacteroides fragilis | 1 | 1997 | 3 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 44 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 40 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2016 | 42 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 32 | 0.030 |
Why?
|
| Integrases | 1 | 2016 | 39 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2016 | 12 | 0.030 |
Why?
|
| Lactococcus lactis | 1 | 1996 | 2 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 70 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1996 | 25 | 0.030 |
Why?
|
| Stem Cells | 1 | 2016 | 123 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1996 | 242 | 0.030 |
Why?
|
| Dermatomycoses | 1 | 1995 | 3 | 0.030 |
Why?
|
| Mucormycosis | 1 | 1995 | 6 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1995 | 17 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 585 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 355 | 0.030 |
Why?
|
| Cell Division | 1 | 1995 | 154 | 0.030 |
Why?
|
| Prospective Studies | 1 | 1998 | 1280 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1996 | 72 | 0.030 |
Why?
|
| DNA Probes | 1 | 1995 | 13 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 1999 | 485 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 122 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 44 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 332 | 0.030 |
Why?
|
| Rhodococcus equi | 1 | 1994 | 2 | 0.030 |
Why?
|
| Actinomycetales Infections | 1 | 1994 | 2 | 0.030 |
Why?
|
| Gene Frequency | 1 | 1995 | 185 | 0.030 |
Why?
|
| Dentists | 1 | 1994 | 6 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 417 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1995 | 97 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 1994 | 28 | 0.030 |
Why?
|
| Nurses | 1 | 1994 | 13 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 667 | 0.030 |
Why?
|
| Medicine | 1 | 1994 | 22 | 0.030 |
Why?
|
| Demography | 1 | 1994 | 94 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 32 | 0.030 |
Why?
|
| Transcriptome | 1 | 2015 | 232 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 469 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 825 | 0.030 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 6 | 0.020 |
Why?
|
| Physicians | 1 | 1994 | 83 | 0.020 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 12 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 202 | 0.020 |
Why?
|
| Penile Neoplasms | 1 | 2013 | 12 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 782 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 2013 | 25 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1994 | 379 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 1994 | 261 | 0.020 |
Why?
|
| Spectinomycin | 1 | 1992 | 4 | 0.020 |
Why?
|
| Self Medication | 1 | 1992 | 4 | 0.020 |
Why?
|
| Mesocricetus | 1 | 1992 | 13 | 0.020 |
Why?
|
| Erythromycin | 1 | 1992 | 15 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 1992 | 36 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2013 | 114 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1032 | 0.020 |
Why?
|
| Blood Donors | 1 | 1992 | 4 | 0.020 |
Why?
|
| Wisconsin | 1 | 1992 | 9 | 0.020 |
Why?
|
| Arizona | 1 | 1992 | 38 | 0.020 |
Why?
|
| Motivation | 1 | 1994 | 216 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 31 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 257 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 78 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 1991 | 53 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 165 | 0.020 |
Why?
|
| Rifampin | 1 | 1991 | 7 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 73 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 78 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 416 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 270 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2011 | 64 | 0.020 |
Why?
|
| Prevalence | 1 | 1992 | 518 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 26 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 304 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 466 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 1469 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 1991 | 118 | 0.020 |
Why?
|
| Penicillin G | 1 | 1989 | 1 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1989 | 50 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 106 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 739 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 469 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 47 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 631 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1992 | 1002 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 737 | 0.020 |
Why?
|
| African Americans | 1 | 2010 | 352 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 292 | 0.020 |
Why?
|
| Child, Preschool | 3 | 1999 | 1174 | 0.020 |
Why?
|
| Cecal Diseases | 1 | 2005 | 4 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 2005 | 7 | 0.010 |
Why?
|
| Wound Infection | 2 | 1995 | 13 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2005 | 77 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 103 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 112 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2004 | 13 | 0.010 |
Why?
|
| Ebolavirus | 1 | 2003 | 8 | 0.010 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2003 | 8 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 274 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2003 | 11 | 0.010 |
Why?
|
| Anthrax Vaccines | 1 | 2003 | 35 | 0.010 |
Why?
|
| Drug Design | 1 | 2003 | 63 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 479 | 0.010 |
Why?
|
| Anthrax | 1 | 2003 | 92 | 0.010 |
Why?
|
| Arenaviridae Infections | 1 | 2002 | 2 | 0.010 |
Why?
|
| Paramyxovirinae | 1 | 2002 | 2 | 0.010 |
Why?
|
| Paramyxoviridae Infections | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hantavirus Infections | 1 | 2002 | 3 | 0.010 |
Why?
|
| Animal Diseases | 1 | 2002 | 4 | 0.010 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Bacillus anthracis | 1 | 2003 | 154 | 0.010 |
Why?
|
| Agriculture | 1 | 2002 | 44 | 0.010 |
Why?
|
| Dog Diseases | 1 | 2001 | 30 | 0.010 |
Why?
|
| Dogs | 1 | 2001 | 510 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 524 | 0.010 |
Why?
|
| Phlebotomy | 1 | 1999 | 3 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 1999 | 4 | 0.010 |
Why?
|
| Clone Cells | 1 | 1999 | 22 | 0.010 |
Why?
|
| Mycobacterium avium Complex | 1 | 1998 | 3 | 0.010 |
Why?
|
| Clarithromycin | 1 | 1998 | 7 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1999 | 55 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1999 | 39 | 0.010 |
Why?
|
| Azithromycin | 1 | 1998 | 11 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 209 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1999 | 158 | 0.010 |
Why?
|
| Bacillus subtilis | 1 | 1997 | 23 | 0.010 |
Why?
|
| Chloramines | 1 | 1976 | 3 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1997 | 121 | 0.010 |
Why?
|
| Bacterial Adhesion | 1 | 1994 | 27 | 0.010 |
Why?
|
| History, 19th Century | 1 | 1994 | 36 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1994 | 6 | 0.010 |
Why?
|
| Cefotaxime | 1 | 1994 | 5 | 0.010 |
Why?
|
| Clindamycin | 1 | 1994 | 6 | 0.010 |
Why?
|
| Cefazolin | 1 | 1994 | 6 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1994 | 84 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1995 | 150 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1994 | 74 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 28 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1994 | 36 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1994 | 43 | 0.010 |
Why?
|
| Radiography | 1 | 1994 | 203 | 0.010 |
Why?
|
| Homosexuality | 1 | 1993 | 1 | 0.010 |
Why?
|
| Child | 1 | 1999 | 2292 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1998 | 2426 | 0.010 |
Why?
|
| Subtilisins | 1 | 1991 | 6 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1991 | 86 | 0.010 |
Why?
|
| Seasons | 1 | 1991 | 94 | 0.010 |
Why?
|
| Immunity | 1 | 1991 | 27 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1991 | 122 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1991 | 2065 | 0.000 |
Why?
|
| Electrochemistry | 1 | 1976 | 14 | 0.000 |
Why?
|
| Blood | 1 | 1976 | 34 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1976 | 79 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1976 | 209 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1976 | 270 | 0.000 |
Why?
|